Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label atomoxetine in children and adolescents with autism spectrum disorder and ADHD symptoms
NL-OMON21784Active, not recruiting
- Sponsor
- Accare
- Start
- Feb 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of atomoxetine in attention deficit hyperactivity disorder (ADHD) and Autism Spectrum Disorder (ASD), sponsored by Accare. Primary endpoint: Change in ADHD-Rating Scale-I. Started Feb 2004; status: active, not recruiting.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NL-OMON21784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21784.